Novartis Can't Apply NJ Punitives Cap In 3 Zometa Suits
By Andrew Scurria (November 26, 2013, 1:54 PM EST) -- Pennsylvania product liability law permitting unlimited punitive damages controls three suits alleging Novartis Pharmaceuticals Corp.'s bone drug Zometa caused jaw injuries, a federal judge said Friday, denying the drugmaker's attempt to apply softer New Jersey law.
U.S. District Judge Mark. R. Hornak applied Pennsylvania law to the suits despite arguments from Novartis that New Jersey, home to its U.S. headquarters, bore the more significant relationship to the punitive damages issue as the site of the alleged corporate misconduct.
The ruling effectively removes a punitive-damages cap of $350,000 or five times the compensatory award, whichever is greater, afforded by the New Jersey...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!